Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QT Prolongation Trial For All Drugs Recommended By ICH Draft Guidance

Executive Summary

All drugs should undergo a single cardiac QT interval prolongation trial early in development, an International Conference on Harmonization draft guidance on clinical evaluation of QT prolongation, released Sept. 13, states

You may also be interested in...

FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs

The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.

FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes

A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.

FDA Needs Bigger Window To The Public, Say Deputies

FDA may be looking to expand the scope of public discussion in the development of regulatory policy regarding emerging scientific issues

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts